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Charcot-Marie-Tooth disease (CMT) is the most common form of inherited motor and sensory neuropathy. 
Moreover, CMT is a genetically heterogeneous disorder of the peripheral nervous system, with many genes identified 
as CMT-causative. CMT has two usual classifications: type 1, the demyelinating form (CMT1); and type 2, the axonal 
form (CMT2). In addition, patients are classified as CMTX if they have an X-linked inheritance pattern and CMT4 if 
the inheritance pattern is autosomal recessive. A large amount of new information on the genetic causes of CMT 
has become available, and mutations causing it have been associated with more than 17 different genes and 25 
chromosomal loci. Advances in our understanding of the molecular basis of CMT have revealed an enormous 
diversity in genetic mechanisms, despite a clinical entity that is relatively uniform in presentation. In addition, recent 
encouraging studies - shown in CMT1A animal models - concerning the therapeutic effects of certain chemicals have 
been published; these suggest potential therapies for the most common form of CMT, CMT1A. This review focuses 
on the inherited motor and sensory neuropathy subgroup for which there has been an explosion of new molecular 
genetic information over the past decade.
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INTRODUCTION
Charcot-Marie-Tooth disease (CMT) is the most 
common form of inherited motor and sensory neuro-
pathy.
1 CMT is genetically and clinically a heterogeneous 
disorder of the peripheral nervous system, and mutations 
of many CMT genes are known to be responsible for the 
development of a variety of distinct phenotypes.
2 In 
1886, Charcot and Marie in France and, independently, 
Tooth in the United Kingdom described hereditary motor 
and sensory neuropathies for the first time (Fig. 1).
3,4 
Today, the classification of CMT has been revised and 
extended based on clinical features and electrophysio-
logical, histopathological, and genetic findings.
5 
Autosomal-dominant inherited CMT is usually classified 
as type 1, the demyelinating form (CMT1), or type 2, 
the axonal form (CMT2).
6 CMT1 patients have severely 
reduced nerve conduction velocities (NCVs). The upper 
limit of NCV for the motor median nerve in CMT1 
patients is 38 m/s.
7 Histopathological examinations of 
peripheral nerve biopsies frequently reveal extensive 
segmental demyelination and remyelination.
8 The primary 
defect of CMT2 patients is neuronal.
9 We classify 
patients as having CMTX if they have an X-linked 
inheritance pattern, and CMT4 if the inheritance pattern Lee JH and Choi BO. Charcot-Marie-Tooth Disease: Seventeen Causative Genes  
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Figure 1. Contemporary portraits of Charcot (A), Marie (B), and Tooth (C). In 1886, Frenchmen Jean Martin Charcot (1825~1893) and
Pierre Marie (1853~1940), and Briton Howard Henry Tooth (1856~1925), described hereditary motor and sensory neuropathies for the
first time.
is autosomal recessive.
9 
Considerable new information about the pathophysiology 
and causative genes of CMT has recently become 
available.
2 To date, mutations causing inherited neuro-
pathies have been associated with at least 17 different 
genes, and chromosomal loci have been identified in 
more than 25 others (see Table 1).
6 These investigations 
are helpful not only for the pathophysiologic studies of 
peripheral neuropathies but also the clinical and genetic 
classification of complex peripheral nerve disease. 
Onapristone, ascorbic acid, and neurotrophin-3 (NT3) 
have recently been introduced for the treatment of 
CMT.
10-12 In this review, we focus on the 17 gene 
mutations that are known to cause CMT, and discuss the 
biological mechanisms of the peripheral neuropathies 
associated with myelin and axons. 
GENES ASSOCIATED WITH 
DEMYELINATING NEUROPATHY
Myelin plays an important role in the saltatory trans-
mission of impulses along neuronal extensions.
8 As part 
of the process of myelination, myelin-forming Schwann 
cells trap large-caliber axons within their plasma mem-
branes during the development of the peripheral nervous 
system.
13 Faulty communication between Schwann cells 
and neurons, due to genetic defects, frequently leads to 
these peripheral neuropathies.
8 
1.  PMP22
The peripheral myelin protein 22 (PMP22) gene is 
located within the duplication region. Several lines of 
evidence implicate alterations in gene dosage of PMP22 
as the main factor underlying the CMT1A phenotype.
14,15 
This means that patients carrying one extra copy of 
PMP22 develop CMT1A, while patients with HNPP 
(hereditary neuropathy with liability to pressure palsies) 
deletion have only one copy of PMP22 (Fig. 2). 
1)  PMP22 duplication
Tandem duplication of the CMT1A region within 
chromosome 17p11.2-p12, including the PMP22 gene, is 
the most frequent cause of CMT type 1.16 This dupli-
cation is caused by an unequal crossover event between 
two homologous repetitive elements flanking the 1.4-Mb 
region.
16 Approximately 50% of all CMT patients have 
this duplication, as do at least 70% of all patients with 
CMT1.
17 Patients carrying one extra copy of PMP22 Journal of Clinical Neurology: Vol. 2, No. 2, 2006
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Figure 2. (A) CMT1A duplication and HNPP deletion are reciprocal products of a recombination event (unequal crossing-over) during
meiosis, mediated by the flanking repeat elements (CMT1A-REPs). (B) Genomic map of the chromosome 17p11.2-p12. The genomic 
structure of the CMT1A/HNPP region (telomere-to-centromere orientation). Proximal and distal CMT1A-REPs are shown as vertical boxes.
develop CMT1A, whereas entire, or even partial, deletion 
of the 17p11.2-p12 region causes HNPP. Duplication or 
deletion of the 1.4-Mb fragment is the primary causative 
mutation, but it is not found in all cases of CMT1A and 
HNPP.
18 In rare cases, missense or frame-shift mutations 
in the PMP22 gene lead to CMT1A and HNPP.
19,20 The 
symptoms occurring in mice carrying an additional copy 
of  PMP22 are similar to those of patients with human 
peripheral myelin protein duplication.
21
It has been reported that the administration of the 
selective progesterone receptor antagonist onapristone 
reduces overexpression of PMP22 and impairs the CMT 
phenotype, without obvious side-effects.
10 In addition, 
Passage et al. reported, with their mouse model of 
CMT1A, that ascorbic acid had an important effect in 
myelination and in reducing PMP22 concentrations to Journal of Clinical Neurology: Vol. 2, No. 2, 2006
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levels below those necessary to induce the disease 
phenotype.
11 
2)  PMP22 deletion
HNPP patients are characterized by recurrent pressure 
palsies and nerve biopsies from them show sausage-like 
swellings (tomacula) of the myelin sheaths.
22 Deletion of 
the chromosome 17p11.2-p12 region that includes PMP22 
frequently provides the genetic basis of hereditary 
peripheral demyelinating neuropathy such as HNPP (Fig. 
2).
23,24 Mutations and altered dosage of the PMP22 gene 
are regarded as the main reasons for hereditary peripheral 
neuropathies.
25,26 Deletion is the most frequent mutation, 
but is not found in all cases of HNPP. In rare cases, 
frame-shift mutations in the PMP22 gene lead to 
HNPP.
19,20 
Clinical assessments of HNPP patients are generally 
less severe than those of CMT1A patients.
26-28 HNPP 
usually develops as a painless neuropathy after minor 
trauma or compression. The mean ages of onset of 
HNPP and CMT1A are not significantly different; 
however, onset in the preteens was found to be more 
frequent in CMT1A than in HNPP.
27,28 
3)  PMP22 point mutation
Although the point mutation of the PMP22 gene is 
rare, it is also a cause of CMT1A and HNPP.
19,20,29 
Patients carrying the PMP22 point mutation of the 
PMP22 gene show similar clinical features to those 
carrying duplication or deletion.
20,29 However, in rare 
cases, patients with PMP22 point mutations show an 
early age of onset and severe phenotypes, such as 
Déjérine-Sottas syndrome (DSS).
30 In addition, audio-
logical evaluation can reveal auditory neuropathy in the 
affected individual with a frame-shift mutation Ala106fs 
(318delT) in the PMP22 gene.
31 
2.  EGR2 
The early growth response 2 (EGR2) gene encodes a 
zinc finger transcription factor that plays a major role in 
myelination of peripheral nerves.
32 EGR2 mutations are 
associated with a dominantly inherited severe form of 
CMT1, giving syndromes of congenital hypomyelination 
(CH), DSS, or CMT4E with recessive inheritance.
33 
Disruption of the EGR2 gene in mice blocks the 
development of Schwann cells at the promyelinating 
stage and causes demyelinating peripheral neuropathy by 
preventing PNS myelination.
34 Thus, the normal expres-
sion of the EGR2 gene is very important in the process 
of Schwann cell development.
34 In a recent study, 
overexpression of EGR2 in Schwann cells strongly 
increased the expression of other myelin-related genes; 
therefore,  EGR2 mutation may cause a demyelinating 
form of CMT.
35
A CMT family with two missense mutations in 
different genes has been reported.
36 A R359W mutation 
in  EGR2 was shared by the affected daughter and her 
father. In addition, she had a V136A mutation in GJB1, 
which was determined to be a de novo mutation. The 
daughter with two different gene mutations showed more 
severe clinical, electrophysiological, and histopatho-
logical phenotypes than her father, who had only the 
EGR2 mutation. These phenotypic differences between 
the proband and her father may have been caused by an 
altered effect of the genetic modifier in EGR2, or by the 
additive effect of the EGR2 and GJB1 mutations.
36 
The  EGR2 gene regulates the expressions of myelin 
genes, including GJB1,  PMP22, P0, and PRX in a 
dominant-negative manner.
37,38 Mutations in EGR2 
prevent Schwann cell development, and lead to the 
development of demyelinating neuropathy via the 
regulation of GJB1 expression (Fig. 3).
37 Moreover, it is 
known that the R359W mutation in EGR2 reduces 
transcriptional activity in GJB1.
38 
3.  LITAF 
Mutations in the LITAF (lipopolysaccharide-induced 
tumor necrosis factor-alpha factor, also referred to as 
SIMPLE) gene cause the demyelinating autosomal 
dominant disease CMT1C.
9 Patients with CMT1C have 
decreased NCVs of 20~25 m/s, along with mild weakness 
and sensory loss that first presents within the first two 
decades of life.
39 They show very similar clinical 
findings to CMT1A. SIMPLE is a protein encoded by 
the  LITAF gene and may interact with Nedd4, an E3 
ubiquiton ligase.
40 Although SIMPLE is expressed in Lee JH and Choi BO. Charcot-Marie-Tooth Disease: Seventeen Causative Genes  
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Figure 3. Genomic structures of GJB1 (A) and EGR2 (B). The EGR2 gene encodes a zinc finger transcription factor that plays a major
role in myelination of the peripheral nerves, and the EGR2 gene regulates the expressions of GJB1. Thus, mutations in EGR2  prevent
Schwann cell development and lead to the development of demyelinating neuropathy (C).
many cell types, when mutated it seems to cause only 
a demyelinating neuropathy. The disease specificity may 
result from the impaired degeneration of specific Shwann 
cell proteins.
40 
4.  PRX
CMT4F is a severe from of recessive CMT that has 
been defined in a large Lebanese family with mutations 
in the periaxin (PRX) gene on chromosome 19.
41 Nerve 
conduction is markedly slowed and onion bulbs are 
observed on sural nerve biopsies. PRX is a protein 
specifically expressed by myelinating Schwann cells.
42 
In adult myelinated fibers, PRX is found in the abaxonal 
membrane.
38 During development, PRX is found in the 
adaxonal membrane or periaxonal cytoplasm of the 
myelinating Schwann cell and may have some additional 
function.
43,44 Furthermore, an isoform of PRX is targeted 
to the nucleus of embryonic Schwann cells, suggesting 
that this protein can shuttle between the nucleus and 
cortical signaling or adherence complexes. Histopatho-
logical analysis of a nerve biopsy from a CMT4F patient 
revealed disruption of the connection between the 
paranodal loop and the adjacent axon; structural abnor-
mality of the paranode was also present.
45
5.  MTMR2
Mutations in the gene encoding myotubularin-related 
phosphatase 2 (MTMR2) cause a severe autosomal- 
recessive, demyelinating neuropathy, CMT4B1, which 
has also been called hereditary motor and sensory neuro-
pathy with focally folded myelin sheaths.
46  MTMR2 
contains a homologous 10-amino acid sequence with an 
active site for both tyrosine and serine phosphate.
47 The 
function of MTMR2 is not yet known. However, teased 
fibers from sural nerve biopsy samples showed segmental 
demyelination associated with redundant loops of 
myelin, suggesting that MTMR2 has an important role in 
the regulation of myelin wrapping.
48 
6.  SBF2
Mutations in MTMR13/SBF2 have been identified 
in severe autosomal recessive demyelinating CMT, 
CMT4B2.
49 SBF2 is located on chromosome 11p15 and 
is also known as myotubulin-related protein 13 (MTMR13). 
MTMR13/SBF2 is a homologue of MTMR2, which Journal of Clinical Neurology: Vol. 2, No. 2, 2006
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Figure 4. Genomic structure and mutations of MFN2. Solid black boxes and solid white boxes indicate protein coding sequences and
untranslated sequences, respectively. P, loop; GTP, binding-site motif; Cc, coiled-coil domain; TM, transmembrane domain; GTPase, 
GTPase functional domain; fzo mitofusin, fzo mitofusin functional domain. 
causes CMT4B1.
49 This is probably the reason for 
CMT4B2 neuropathy resembling that of CMT4B1 both 
clinically and pathologically. These peripheral neuro-
pathies show very severe disabilities in infancy and 
extremely slow NCVs. Sometimes patients are wheelchair- 
bound by adulthood. Because the pathological findings 
of CMT4B1 and CMT4B2 are found simultaneously 
with the misfoldings of myelin, they probably share a 
common pathological mechanism. SBF2 might regulate 
phosphatase activity by interacting with MTMR2.
9 
GENES ASSOCIATED WITH
AXONAL NEUROPATHY
1.  MFN2
By linkage analysis and screening genes linked to the 
CMT2A locus, Züchner et al. first identified several 
mutations in the mitofusion 2 (MFN2) gene.
50 Subse-
quently, additional MFN2 mutations were reported in 
CMT2A patients (Fig. 4).
51,52 Thus, mutations in MFN2 
are now considered to provide the genetic basis of the 
CMT2A phenotype. Mitofusin 2 encodes an outer mito-
chondrial membrane protein which, in cooperation with 
the MFN1 isoform, has important roles in the regulation 
of mitochondrial fusion,
53-55 a function essential for 
metabolic activity in eukaryotic cells.
56 It has also been 
suggested that MFN2 may be associated with main-
taining mitochondrial membrane potentials.
57 Moreover, 
MFN2-deficient mice die in mid-gestation and display 
fragmented mitochondria.
54 It is also believed, from a 
few population-based studies, that MFN2 mutations are 
most common in CMT2.
58 Recently, axonal CMT 
neuropathy with visual impairment due to optic atrophy - 
designated as hereditary motor and sensory neuropathy 
type VI (HMSN VI) - has also been shown to be caused 
by mutations in the MFN2 gene.
59 It is well known that 
HMSN VI is an axonal CMT neuropathy with optic 
atrophy. However, the differences between CMT2A and 
HMSN VI with MFN2 mutations remain to be clarified. 
It appears that mutational loci with high frequency might 
exist in MFN2 at the 94th, 105th, 280th, and 364th 
codons.
60 
Ethnic population data on MFN2 mutations are 
limited because the relevance of the MFN2 mutation to 
CMT2 has been reported only recently.
50 Züchner et al. 
reported 7 mutations (19%) in 36 CMT2 families repre-
senting several ethnic groups; a Japanese group reported 
7 mutations (9%) in 81 axonal or unclassified CMT 
patients,
47 and an American study found 3 mutations 
(23%) in 13 CMT2 families.
50-52 In addition, MFN2 
mutations have been identified in 22% of Korean CMT2 
families.
60 The mutation frequency observed by the 
Japanese group was lower than that found in the other 
studies, which may be due to sampling or analytical Lee JH and Choi BO. Charcot-Marie-Tooth Disease: Seventeen Causative Genes  
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differences or perhaps to different genetic backgrounds. 
Kijima et al. performed denaturing high-performance 
liquid chromatography (HPLC) prior to sequence 
analysis, a process that may have reduced the detection 
rate.
51 
Mutations in the MFN2 gene are now viewed as the 
primary cause of axonal autosomal-dominant CMT2A, 
and it has therefore been suggested that these patients 
should be screened for MFN2. However, clinical and 
electrophysiological phenotypes of CMT patients with 
MFN2 mutations were significantly different in early- 
and late-onset groups, and optic atrophy was found only 
in CMT2 patients with unusually severe phenotypes with 
an early onset age. In addition, MFN2 mutations show 
variable central nervous system (CNS) involvements. 
2.  KIF1B 
Following the mapping of CMT2A to the short arm 
of chromosome 1, 1p35-p36, a missense mutation was 
detected in KIF1B in a Japanese CMT2A family.
61 
However, no other mutation has been identified in 
KIF1B, and it is therefore believed that another gene is 
involved.
62,63 The kinesin superfamily is responsible for 
microtubule-dependent transport of a variety of organelles 
and vesicles. 
3.  RAB7 
It has been reported that mutations in the ras-related 
protein rab-7 (RAB7) gene cause the axonal form of 
CMT known as CMT2B.
64  RAB7 is a member of the 
Rab family of small G proteins, which regulate intra-
cellular vesicle traffic. RAB7 and its effector protein, 
RILP, have been shown to play a role in lysosomal 
transport by inducing the recruitment of dynein-dynactin 
motors.
65 Mutations in dynactin also cause axonopathy, 
suggesting that two separate diseases may share a com-
mon pathway.
4.  sHSP27 
Mutations of the small heat-shock proteins (sHSPs) 
are reported to cause either CMT2 or a distal hereditary 
motor neuropathy (dHMN).
66 It is known that sHSPs are 
part of a protein superfamily sharing 85 amino acid 
residues in a C-terminal region known as the α - 
crystalline domain, although the function of sHSP is 
unclear. However, it is believed that sHSP27 is 
associated with protection from apoptosis and stabili-
zation of the cytoskeleton.
67 Irobi et al.
66 reported that 
mutations in the α -crystalline domain of sHSP22 cause 
dHMN type II; Evgrafov et al.
68 suggested that muta-
tions in the α -crystalline and C-terminal tail of sHSP27 
cause either CMT2F or another dHMN. It seems that 
sHSP22 and sHSP27 interact with each other, and both 
diseases involve common mechanisms.
69,70 
5.  Glycyl-tRNA synthetase
Glycyl-tRNA synthetase is known to cause CMT2D.
71 
In four families with CMT2D, mutation of Glycyl-tRNA 
synthetase provided the first example of an aminoacyl 
tRNA synthetase which was related to human genetic 
disease.
71 Why a mutation in a tRNA synthetase should 
cause only a chronic neuropathy but spare other organ 
systems is both unknown and surprising.
GENES ASSOCIATED WITH BOTH 
DEMYELINATING AND AXONAL NEUROPATHIES
1.  MPZ 
Mutations in the myelin protein zero (MPZ) gene, 
which is located on chromosome 1q21-q22, are present 
in CMT1B, CMT type 2, DSS, and CH neuropathy.
72,73 
It is proposed that the nature and position of the MPZ 
mutations largely determine the axonal and demyelina-
ting phenotypes. MPZ is highly expressed by myelinating 
Schwann cells and in more than half the protein in the 
peripheral myelin sheet. The clinical, electrophysiological, 
and histopathological findings appear to be hetero-
geneous for MPZ mutations.
74 Furthermore, the same 
mutation can cause different degrees of disease severity 
in different patients.
75 
The protein consists of 248 amino acids and a single 
extracellular immunoglobulin-related domain (which Journal of Clinical Neurology: Vol. 2, No. 2, 2006
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Figure 5. Structure of the NEFL protein, which is one of the 
most abundant cytoskeletal components of the neuron. The 
NEFL gene encoding the neurofilament light chain plays an 
important role in axonal structure, including an extensive fibrous 
network in the cytoplasm of the neuron.
mediates homophilic adhesion), a transmembrane domain, 
and a short basic intracellular domain.
76 MPZ knock-out 
mice show abnormal regulation of myelin gene expres-
sion such as upregulation of MAG and PLP and down-
regulation of PMP22.
77 The myelination regulatory 
mechanism of MPZ is through adhesion-mediated signal 
transduction.
78 By this hypothesis, the in vitro mutations 
of  MPZ are associated with decreased MPZ-mediated 
adhesion and these changes cause the more severe 
clinical features.
2.  NEFL
Neurofilament light-chain polypeptide (NEFL) is one 
of the most abundant cytoskeletal components of the 
neuron.
79 The NEFL gene encoding the neurofilament 
plays an important role in axonal structure, including 
that of the extensive fibrous network in the cytoplasm of 
the neuron (Fig. 5).
79 Mutations in the NEFL gene 
usually cause axonal CMT2E neuropathy, but recent 
studies found that NEFL mutations cause the demye-
linating forms of neuropathy common to CMT1 and 
DSS.
80 
Nerve conduction studies of CMT2E patients showed 
that NCV is not decreased severely. These findings 
suggest that the pathophysiological mechanism of the 
neuropathy is primary axonal damage.
81 A patient with 
NEFL gene mutation shows proximal muscle weakness, 
normal NCV, and reduced motor and sensory nerve 
action potential amplitudes, findings compatible with 
typical CMT2. Transgenic mice harboring loss of NEFL 
genes show a normal phenotype; however, NCVs are 
severely reduced.
82,83 Mutation of the NEFL gene could 
be the cause of both CMT1 and CMT2 neuropathies. 
Population data on the mutation frequencies of the 
NEFL gene are very limited. The frequencies of NEFL 
were 4.8% in Koreans and 2.2% in Caucasian CMT 
patients.
84,85 
3.  GJB1
CMTX is the second-most-frequent form of CMT, 
and is caused by mutations in the gene for gap junction 
protein beta 1 (GJB1: connexin 32, Cx32), which maps 
to chromosome Xq13.
86,87 CMTX patients display the 
distinctive criterion of an X-linked mode of inheritance; 
that is, an absence of man-to-man transmission and a 
more severe disease phenotype in affected males than in 
affected females of the same age.
88 Motor nerve con-
duction is slower in CMTX males, but ranges from 
slightly reduced to normal in females.
89 The nature of 
the neuropathy in CMTX remains controversial, and it 
could be a primary axonal neuropathy or a primary 
demyelinating neuropathy with secondary axonal 
degeneration.
90,91
The  GJB1 gene is involved in the transport of small 
molecules within Schwann cells.
92 Gap junctions allow 
electrical communication between cells in the nervous 
system and GJB1 mutations affect the function of gap 
junctions in the myelin sheath.
93 Gap junctions comprise 
intercellular channels among adjacent cells and they are 
distributed in the liver, kidneys, and CNS as well as the 
peripheral nerves.
94 Since the GJB1 gene is expressed 
not only in Schwann cells but also in oligodendrocytes, 
GJB1 mutation has been reported to cause CNS 
lesions.
95 There are over 200 mutations associated with 
various degrees of muscular weakness, atrophy, and 
sensory impairment. In studies of CMTX patients, muta-Lee JH and Choi BO. Charcot-Marie-Tooth Disease: Seventeen Causative Genes  
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tion of GJB1 more or less destroyed the structure of the 
myelin and the action potential amplitude was more 
affected than the NCV.
96 Sural nerve biopsy confirmed 
that there was prominent axonal loss.
97 
The mutation frequency of GJB1 in Korea (7.1%)
85 is 
considerably lower than in several European groups -
Spain, 21.3%
98; Finland, 19.0%
99; Russia, 13.0%
100; 
Italy, 16.7%
101; Germany, 11.9%
102 - but is similar to that 
in Japan (5.6~5.7%).
103,104 It appears that mutations in 
GJB1 are less frequent in East Asian CMT patients than 
in European patients. 
4.  GDAP1 
CMT4A is linked to 8q13-q21.1 and is caused by 
mutations in ganglioside-induced differentiated associated 
protein 1 (GDAP1), a novel protein of unknown func-
tion.
105 Clinical symptoms begin at an early age (before 
10 years), with delayed developmental milestones of 
sitting or walking; weakness spreads to proximal muscles 
by the end of the first decade. However, sensory loss is 
mild. In other patients, hoarse voice and vocal cord 
paresis have been reported. Axonal and demyelinating 
phenotypes have been associated with GDAP1 muta-
tions, which could be the cause of both the demye-
linating and axonal neuropathies.
106 The GDAP1 gene is 
found in the nerve cell at an early stage of development 
but its expression is found in the Schwann cell.
107 It is 
not yet known if mutation of the GDAP1 gene damages 
the nerve cell, Schwann cell, or both. However, a likely 
hypothesis is that mutation of the GDAP1 gene disturbs 
signal transmission between Schwann cells and nerve 
cells.
GENES WITH UNKNOWN FUNCTION
1.  Gigaxonin
Mutations in the Gigaxonin gene lead to a rare 
autosomal-recessive giant axonal neuropathy (GAN) 
affecting the peripheral nervous system and CNS.
108 
Prominent axonal swelling occurs, with masses of tightly 
woven neurofilaments - commonly found near nodes of 
Ranvier - producing an increase in axon caliber.
109 This 
causes the main stigmata of the disease. Abnormalities 
in the organization of neurofilaments are also found in 
the brains of these patients, and are the possible cause 
of the associated mental retardation. 
GAN includes abnormal intermediate neurofilaments 
and displays the typically kinky-hair-like filaments. The 
mechanism of the disease is unknown, but the peripheral 
neuropathy is developed by the mutation of the Gigaxonin 
gene, which possibly induces changes in the axon 
transport system and a resulting deficiency in energy.
2.  KIAA1985
CMT4C is caused by homozygous or compound hetero-
zygous mutations in the previously uncharacterized 
KIAA1985 gene.
110 CMT4C is a childhood-onset disease 
associated with an early-onset scoliosis and a distinct 
Shwann cell pathology. Scoliosis is prominent early on 
and may precede weakness and sensory loss. The protein 
encoded by KIAA1985 belongs to new vertebrate protein 
group whose function is not known. By means of com-
parative sequence alignment, it is possible to determine 
that this protein group includes the multiple SH3 and 
TRP domains which are associated with formation of 
protein polymers.
110
CONCLUSIONS
Seventeen genes that cause hereditary motor and 
sensory neuropathy have been described. Even though 
the severities of the clinical symptoms differ, CMT is 
caused by a single gene mutation and follows Mendel’s 
law. Development of the disease is directly due to a 
genetic defect, which means that detection of the defect 
provides a positive diagnosis. Over the past decade, new 
information about the function of genes known to cause 
CMT and new rational treatment approaches for CMT1A 
have emerged.
10-12 Apparent therapeutic effects of certain 
chemicals tested in CMT1A animal models highlight the 
importance of exact and speedy determination of chromo-
some 17p11.2-p12 duplication in subjects with peripheral 
neuropathies.
10,11 A personalized therapy for patients Journal of Clinical Neurology: Vol. 2, No. 2, 2006
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with CMT1A duplication might be possible in the near 
future. For this reason, the importance of rapid and 
accurate molecular diagnosis is again emphasized. 
Understanding mutations and their causes and clarifying 
the pathophysiologic mechanisms of CMT is important 
not only for diagnosis but also for developing new 
therapies.
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